The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso
Open accessAbstract
El síndrome hemolítico urémico (SHU) es una entidad clínica definida por la tríada anemia hemolítica no inmune, trombocitopenia e insuficiencia renal aguda, en la que las lesiones subyacentes están mediadas por un proceso de microangiopatía trombótica (MAT) sistémico. Distintas causas pueden desencadenar el proceso de MAT que caracteriza el SHU. En este documento consideramos SHU atípico (SHUa) como el subtipo de SHU en el que los fenómenos de MAT son fundamentalmente consecuencia del daño producido en el endotelio de la microvasculatura renal y de otros órganos por desregulación de la actividad del sistema del complemento. En los últimos años se han identificado diversas mutaciones en genes del sistema del complemento asociados a SHUa, que explicarían aproximadamente el 60% de los casos de SHUa, y se han caracterizado funcionalmente numerosas mutaciones y polimorfismos asociados a SHUa que han permitido determinar que la patología se produce como consecuencia de la deficiente regulación de la activación del complemento sobre las superficies celulares y que lleva al daño endotelial mediado por la activación del C5 y de la vía terminal del complemento. Eculizumab es un anticuerpo monoclonal humanizado que inhibe la activación del C5, bloqueando la generación de la molécula proinflamatoria C5a y la formación del complejo de ataque de membrana. En estudios prospectivos en pacientes con SHUa su administración ha demostrado la interrupción rápida y sostenida del proceso de MAT, con una mejora significativa de la función renal a largo plazo y una reducción importante de la necesidad de diálisis y el cese de la terapia plasmática. En función de las evidencias científicas publicadas y la experiencia clínica acumulada, el Grupo Español de SHUa publicamos un documento de consenso con recomendaciones para el tratamiento de la enfermedad (Nefrología 2013;33(1):27-45). En la presente versión online del documento se actualizan los contenidos sobre la clasificación etiológica de las MAT, la fisiopatología del SHUa, su diagnóstico diferencial y su manejo terapéutico. Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Different causes can induce the TMA process that characterizes HUS. In this document we consider atypical HUS (aHUS) a sub-type of HUS in which the TMA phenomena are the consequence of the endotelial damage in the microvasculature of the kidneys and other organs due to a disregulation of the activity of the complement system. In recent years, a variety of aHUs-related mutations have been identified in genes of the the complement system, which can explain approximately 60% of the aHUS cases, and a number of mutations and polymorphisms have been functionally characterized. These findings have stablished that aHUS is a consequence of the insufficient regulation of the activiation of the complement on cell surfaces, leading to endotelial damage mediated by C5 and the complement terminal pathway. Eculizumab is a monoclonal antibody that inhibits the activation of C5 and blocks the generation of the pro-inflammatory molecule C5a and the formation of the cell membrane attack complex. In prospective studies in patients with aHUS, the use of Eculizumab has shown a fast and sustained interruption of the TMA process and it has been associated with significative long-term improvements in renal function, the interruption of plasma therapy and important reductions in the need of dialysis. According to the existing literature and the accumulated clinical experience, the Spanish aHUS Group published a consensus document with recommendations for the treatment of aHUs (Nefrologia 2013;33[1]:27-45). In the current online version of this document, we update the aetiological classification of TMAs, the pathophysiology of aHUS, its differential diagnosis and its therapeutic management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Syndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Furlan, M., Robles, R., & Lamie, B. (1996) · Blood · doi:10.1182/blood.v87.10.4223.bloodjournal87104223 · Cited by 895
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Atypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810739 · Cited by 554
Anti–Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome
Dragon-Durey, M.-A. G. A., Loirat, C., Cloarec, S., Macher, M.-A., Blouin, J., Nivet, H., Weiss, L., Fridman, W. H., & Frémeaux-Bacchi, V. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004050380 · Cited by 502
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Fakhouri, F., Hourmant, M., Campistol, J. M., Cataland, S. R., Espinosa, M., Gaber, A. O., Menne, J., Minetti, E. E., Provôt, F., Rondeau, E., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.034 · Cited by 305
Self-citationA systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003573 · Cited by 110
Metadata
- Authors
- Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., Román, E., Torra, R., Valdés, F., Vilalta, R., & Rodríguez de Córdoba, S.
- Venue
- Nefrología
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 35
- Issue
- 5
- Pages
- 421-447
- ISSN
- 0211-6995 (ISSN-L)
- OpenAlex
- W2159884188
- Cited by
- 272
- References
- 79
- FWCI
- 13.33
- Type
- journal article
- Language
- es
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. https://app.cochat.ai/papers/10.1016/j.nefro.2015.07.005
- The paper
- Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., Román, E., Torra, R., Valdés, F., Vilalta, R., & Rodríguez de Córdoba, S. (2015). Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. Nefrología. https://doi.org/10.1016/j.nefro.2015.07.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.